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ABSTRACT
Objective: To investigate whether patients with behavioral variant frontotemporal dementia
(bvFTD) have dysregulation in satiety-related hormonal signaling using a laboratory-based
case-control study.
Methods: Fifty-four participants (19 patients with bvFTD, 17 patients with Alzheimer disease
dementia, and 18 healthy normal controls [NCs]) were recruited from a tertiary-care dementia clinic.
During a standardized breakfast, blood was drawn before, during, and after the breakfast protocol to
quantify levels of peripheral satiety-related hormones (ghrelin, cortisol, insulin, leptin, and peptideYY)
and glucose. To further explore the role of patients’ feeding abnormalities on hormone levels, patients
were classified into overeating and nonovereating subgroups based on feeding behavior during sep-
arate laboratory-based standardized lunch feeding sessions.
Results: Irrespective of their feeding behavior in the laboratory, patientswith bvFTD, but not patients
with Alzheimer disease dementia, have significantly lower levels of ghrelin and cortisol and higher
levels of insulin compared with NCs. Furthermore, while laboratory feeding behavior did not predict
alterations in levels of ghrelin, cortisol, and insulin, only patients with bvFTD who significantly over-
ate in the laboratory demonstrated significantly higher levels of leptin compared with NCs, suggest-
ing that leptin may be sensitive to particularly severe feeding abnormalities in bvFTD.
Conclusions: Despite a tendency to overeat, patients with bvFTD have a hormonal profile that
should decrease food intake. Aberrant hormone levels may represent a compensatory response
to the behavioral or neuroanatomical abnormalities of bvFTD. Neurology® 2014;82:512–520
GLOSSARY
ACC 5 anterior cingulate cortex; AD 5 Alzheimer disease; BED 5 binge eating disorder; BMI 5 body mass index; bvFTD 5
behavioral variant frontotemporal dementia; CDR 5 Clinical Dementia Rating; dlPFC 5 dorsolateral prefrontal cortex;
EDTA 5 ethylenediaminetetraacetic acid; MMSE 5 Mini-Mental State Examination; NC 5 normal control; NPI 5 Neuropsy-
chiatric Inventory; PFC 5 prefrontal cortex; PYY 5 peptide YY; RIA 5 radioimmunoassay; UCSF 5 University of California,
San Francisco; VTA 5 ventral tegmental area.
Behavioral variant frontotemporal dementia (bvFTD) is characterized by progressive behavioral
changes, including pronounced feeding abnormalities.1 Despite the fact that more than 80% of
patients with bvFTD develop feeding abnormalities during the course of their illness,2 the
neurohormonal mechanisms and consequences of these abnormalities remain unknown.
Several hormones are implicated in the regulation of feeding behavior. Ghrelin and cortisol pro-
mote food intake whereas insulin, leptin, and peptide YY (PYY) are anorectic hormones that typ-
ically reduce food intake.3 Additionally, glucose, while not a hormone, is also a key regulator of
food consumption, independent from insulin.4 Laboratory studies show that these hormones
directly influence reward-related and cognitive control brain circuits.3–7 However, there have been
no human neuroanatomical lesion studies investigating the effects of focal neurodegeneration on
peripheral satiety hormone levels. The bvFTD pathology is characterized by dysfunction of reward
and regulatory circuits8,9 and presents a unique opportunity to elucidate this important neuro-
hormonal system.
From the Departments of Psychiatry (J.D.W.), Physiology (M.D.), and Neuroscience (M.D.), and Department of Neurology, Memory and Aging Center
(B.K.K., A.N., A.K., B.L.M., K.P.R.), University of California, San Francisco; Department of Psychiatry (J.D.W.), San Francisco Veterans Affairs
Medical Center; and Departments of Molecular Biosciences and Nutrition (P.H.), School of Veterinary Medicine, University of California, Davis.
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We examined whether bvFTD is associ-
ated with dysregulation in ghrelin, cortisol,
insulin, leptin, PYY, and glucose levels using
a laboratory-based controlled study. Control
groups included patients with Alzheimer disease
(AD) dementia, a disorder not typically associ-
ated with overeating, and healthy age-matched
participants. To further characterize feeding
disturbances, we also administered 2 calorically
quantified lunches. Given that behavioral disin-
hibition, including compulsive overeating, in
bvFTD is likely caused by atrophy in frontal
and reward-related brain areas, we hypothesized
that patients with bvFTD would have levels of
satiety-related hormones consistent with a sati-
ated state that should tend to counteract these
behavioral and neuroanatomical abnormalities
(figure 1).
METHODS Standard protocol approvals, registrations,
and consents. All study participants signed an institutional
review board–approved consent form.
Participants. Thirty-six patients with a neurodegenerative disease
(19 with a bvFTD syndrome [meeting international research crite-
ria10] and 17 with AD dementia [meeting National Institute of
Neurological and Communicative Disorders and Stroke–Alzheimer’s
Disease and Related Disorders Association research criteria11]) were
recruited from the University of California, San Francisco (UCSF)
Memory and Aging Center, a dementia specialty clinic. Eighteen
healthy demographically matched caregivers were recruited as control
participants (NC). Patient diagnoses were established by the consen-
sus of a multidisciplinary team comprising neurologists, nurses, neu-
ropsychologists, neuroradiologists, and psychiatrists. Semistructured
caregiver interviews were conducted to ensure accurate diagnostic
histories. Participants with diabetes were excluded. All participants
were evaluated during a 4- to 5-day stay at the UCSF Clinical Care
Research Center. During their inpatient stay, each participant
participated in a 3-day feeding paradigm, consisting of a
standardized breakfast with blood draws on day 2 and 2 successive
lunches on days 3 and 4 (figure 2). Study size was determined by
practical availability of subjects. To maximize power, we included all
potential participants who met the above criteria and could be
assessed within the study’s timeframe for data collection.
Breakfast. Each participant fasted after midnight the night before
the breakfast. At 7:20 AM, an IV was placed and saline locked and
was not removed until after all blood draws. At 8 AM, each partic-
ipant was given a standardized 550-kcal breakfast consisting of
oatmeal, peaches, a hardboiled egg, 3.25% milk, orange juice,
butter, cottage cheese, and decaffeinated tea. Participants were
instructed to complete their meal by 8:30 AM at which time the
food tray was removed. Participants were encouraged to eat the
entire meal (tea optional) within 30 minutes and the quantity of
each food item that remained after the 30 minutes was noted.
Participants underwent blood draws before, during, and after
the breakfast (time point 0 5 delivery of breakfast, approximately
Figure 1 Dysregulated reward circuits in bvFTD
This model diagram depicts how alterations to brain circuits may lead to disinhibition in patients with bvFTD, which in turn may
lead to hormonal changes. In a healthy brain, stimulatory reward circuits such as the VTA, medial OFC, and striatum are bal-
anced by inhibitory circuits such as the medial PFC, dlPFC, and ACC. The pathogenesis of bvFTD may result in an imbalance
of these circuits as the inhibitory regions are early targets of brain atrophy. Moreover, there is evidence supporting a pathologic
enlargement of the VTA in bvFTD. This imbalancemay lead to compensatory alterations in levels of ghrelin, cortisol, and insulin,
as these hormones directly modulate the activity of both the reward-related brain circuits aswell as top-down cognitive control
circuits. ACC5 anterior cingulate cortex; bvFTD5 behavioral variant frontotemporal dementia; dlPFC5 dorsolateral prefrontal
cortex; OFC 5 orbitofrontal cortex; PFC 5 prefrontal cortex; VTA 5 ventral tegmental area.
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8 AM). Two samples were drawn before the breakfast (230
and 25), one was drawn during the breakfast (115), one was
drawn at the end of breakfast (130), and 4 were drawn after
the breakfast was removed (160, 190, 1120, 1180). At each
blood draw, 1 mL was collected in an SST (Serum Separator
Tube) for cortisol assays and 7 mL was collected in an
ethylenediaminetetraacetic acid (EDTA) tube for ghrelin, insulin,
and glucose assays. At time points230 and25 minutes, the 7 mL
collected in the EDTA tube was also used for PYY and leptin assays.
Samples were immediately stored on wet ice and were aliquoted (the
EDTA tube was evenly distributed into separate cryovials for
ghrelin, insulin, PYY, glucose, and leptin) before being placed in a
280°C freezer. The following assays were performed: insulin,
leptin, and PYY levels quantified by radioimmunoassay (RIA)
(Millipore, St. Charles, MO); ghrelin levels, quantified by
RIA (Phoenix Pharmaceuticals, Burlingame, CA); cortisol levels
quantified by RIA (MP Biomedicals, Solon, OH); and glucose
measured with a YSI 2300 glucose analyzer (YSI, Yellow Springs,
OH). For PYY, values from the 2 baseline blood draws were
combined to calculate a single average PYY level. Because of
practical issues involved with blood draws (e.g., temporary blocks
in IV lines, missed collections, and lost samples), only 91% of
planned samples were obtained.
Lunches. Each participant refrained from eating for at least 2 hours
before each lunch. At noon, participants participated in 1 of 2 lunch
feeding paradigms: a nonvariety protocol or a variety protocol
(described previously1). Total caloric intake during each lunch was
calculated. Participants who ate more than 2 SDs above the average
caloric intake of the patients and NCs were classified as “overeaters.”
Medications and body mass index. To establish comparability
among the groups, each participant’s height and weight were mea-
sured to calculate body mass index (BMI). Participants’ waist-to-hip
ratios were calculated from waist measures at the midpoint between
the bottom of the rib cage and the top of the hip bone and hip
measures at the widest part of the hips. A physician documented
each participant’s medications at admission.
Cognitive testing. All patients underwent cognitive, neuropsychiat-
ric, and functional evaluations including the Mini-Mental State
Examination (MMSE), Clinical Dementia Rating (CDR) scale, and
Neuropsychiatric Inventory (NPI). The MMSE measures cognitive
decline, the CDR measures dementia severity, and the NPI is a
caregiver interview that measures neuropsychiatric and behavioral
disturbances.
Statistical analyses conducted. To examine differences between
groups across time points, a random coefficients model using SAS Proc
Mixed (SAS 9.2; SAS Institute Inc., Cary, NC) was used to generate
estimates of hormone levels for each diagnostic group at each time
point, which were compared between the 2 patient groups and the
control group. To correct for multiple comparisons, Fisher least signif-
icant difference was used to test the global hypothesis of each statistical
model at p , 0.05. A deviation statistic was calculated between the
conditionmeansmodel, consisting of the covariates age, sex, and BMI,
and the overall model, consisting of time point, diagnostic group, time
point 3 diagnostic group, age, sex, and BMI. Pairwise comparisons
were performed at the same level of significance only when the devi-
ation statistic was statistically significant, using a Dunnett-Hsu test to
compare patients with NCs.
RESULTS General linear models with Dunnett post
hoc tests did not show differences at a p , 0.05 in
age, BMI, waist-to-hip ratio, education, or percentage
of breakfast calories consumed between patient groups
and NCs (table). Using general linear models with post
hoc Tukey tests comparing across all groups, there were
no differences in CDR scores between diagnostic groups,
although patients with bvFTD had higher NPI total
(F32,1 5 27.92, p , 0.001), NPI eating subscale
(F31,1 5 35.29, p , 0.001), and MMSE (F34,1 5
5.60, p , 0.008) scores than did patients with AD
dementia.
Prophagic hormone levels. Before breakfast, patients
with bvFTD had lower levels of the prophagic hor-
mone ghrelin compared with NCs (figure 3A). Patients
with bvFTD also had lower levels of ghrelin at 115
and 1180 minutes after the delivery of breakfast and
there were nonsignificant trends toward lower levels of
Figure 2 Three-day standardized paradigm consisting of one breakfast and 2 lunches
The breakfast was administered on day 2 of the inpatient admission and was used to assess hormonal responses to food
intake, with each patient having 2 fasting blood draws, 2 blood draws during the breakfast, and 4 postprandial blood draws.
Lunches were used to assess overeating behavior and consisted of an unlimited number of standardized sandwiches admin-
istered on days 3 and 4 of the admission.
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ghrelin in patients with bvFTD compared with NCs at
all other time points during and after themeal (p, 0.10)
(figure 3A). In contrast, patients with AD dementia were
not different than NCs in levels of ghrelin at any time
point. Patients with bvFTD also had lower levels of the
prophagic hormone cortisol before breakfast. After break-
fast, cortisol levels in patients with bvFTD and those with
AD dementia were not different from NCs except at
1180 minutes when both groups showed higher cortisol
values compared with levels in NCs (figure 3C). This
finding is likely because patients began cognitive testing
at 1150 minutes after breakfast delivery. Cortisol levels
are sensitive to cognitive demands. Overall, the hormonal
pattern of low ghrelin and cortisol levels is consistent with
a satiated state and should tend to decrease food intake.
Anorectic hormone levels. Meal intake was associated
with an increase in levels of the anorectic hormone
insulin and glucose in all groups, reaching a peak
30 minutes after the meal (figure 3, E–H). Patients
with bvFTD had higher peak insulin levels (130
and 160 minutes after breakfast) and lower peak glu-
cose levels (130 and 160 minutes after breakfast)
compared with NCs. The increased insulin levels in
bvFTD should tend to decrease food intake and may
contribute to the observed decrease in glucose levels in
patients with bvFTD. Patients with AD dementia had
lower glucose levels at 160 and 190 minutes after
breakfast. However, levels of PYY and leptin were
not different between patients with bvFTD or AD
dementia and NCs at either of the prebreakfast time
points (figure 4, A and C).
Overeaters vs nonovereaters. Five patients with bvFTD
and 2 patients with AD dementia consumed calories
more than 2 SDs above the group mean and were thus
classified as overeaters. The bvFTD overeaters, bvFTD
nonovereaters, and non-bvFTD nonovereaters were
not different from each other in age, BMI, waist-to-
hip ratio, education, CDR scores, or percentage of
breakfast calories consumed (table). However, bvFTD
overeaters had worse behavioral and eating symptoms
as indexed by higher NPI (F29,2 5 12.55, p , 0.001)
and NPI eating subscale (F28,2 5 13.32, p , 0.001)
scores than non-bvFTD nonovereaters. The bvFTD
nonovereaters also showed higher NPI (F29,2 5
12.55, p , 0.001) and NPI eating subscale (F28,2 5
13.32, p , 0.001) scores, as well as lower MMSE
Table Demographics, disease severity, and medicationsa
Normal controls bvFTD AD dementia bvFTD overeaters bvFTD nonovereaters
Non-bvFTD
nonovereaters
No. 18 19 17 5 14 15
Age, y 56.7 6 8.7 58.4 6 11.8 58.6 6 8.0 58.4 6 8.0 58.4 6 13.2 57.0 6 4.9
Sex, M/F 7/11 16/3 9/8 4/1 12/2 7/8
BMI, kg/m2 26.9 6 4.1 27.3 6 3.9 26.3 6 6.1 27.1 6 1.3 27.3 6 4.4 26.7 6 6.1
Waist-to-hip ratio 0.85 6 0.08 0.95 6 0.08 0.89 6 0.08 0.96 6 0.09 0.94 6 0.08 0.89 6 0.08
Education, y 16.1 6 2.6 15.9 6 3.2 14.7 6 2.8 15.6 6 4.8 16.0 6 2.7 14.1 6 2.4
CDR total 1.8 6 0.8 1.4 6 0.8 1.7 6 1.0 1.8 6 0.7 1.4 6 0.8
NPI total 50.5 6 20.5b 19.6 6 11.9 55.6 6 19.6c 48.5 6 21.3c 19.6 6 12.0
NPI eating subscale, % of patients
with minimal/moderate/severe scores
11/33/56b 87/13/0 0/40/60c 15/31/54c 87/14/0
MMSE total 22.4 6 8.2b 14.6 6 7.7 21.6 6 9.5 22.6 6 8.0c 14.6 6 7.7
% Breakfast consumed 82.9 6 6.0 83.9 6 5.9 77.3 6 5.0 93.2 6 11.0 82.0 6 6.7 75.7 6 5.6
Medications, no.
Antidepressants 2 6 7 0 6 6
Antipsychotics 0 3 2 2 1 2
Weight decreasers (topiramate and
bupropion)
0 1 2 0 1 2
Mood stabilizers 0 2 0 0 2 0
Cholinesterase inhibitors (donepezil
and rivastigmine)
0 0 9 0 0 9
Abbreviations: AD 5 Alzheimer disease; BMI 5 body mass index; bvFTD 5 behavioral variant frontotemporal dementia; CDR 5 Clinical Dementia Rating;
MMSE 5 Mini-Mental State Examination; NPI 5 Neuropsychiatric Inventory.
Plus/minus values represent mean 6 SD.
aNo patients were taking stimulants.
bSignificantly different compared to patients with AD.
cSignificantly different compared with non-bvFTD nonovereaters (p , 0.05). NPI eating subscale totals are rank data, thus scores are represented as
percentage of sample in each score tertile: minimal 5 0 or 2/moderate 5 4, 6, or 8/severe 5 12.
Neurology 82 February 11, 2014 515
scores (F30,2 5 3.71, p , 0.04) than non-bvFTD
nonovereaters. NPI eating subscale scores did not
differ between overeating and nonovereating patients
with bvFTD.
Overeating and nonovereating patients with bvFTD
also had similar levels of ghrelin, cortisol, insulin, and
glucose (figure 3, B, D, F, and H). Specifically, both
overeating and nonovereating patients with bvFTD had
lower levels of the prophagic hormone ghrelin at baseline
and nonsignificantly (p , 0.1) lower ghrelin levels
during and after breakfast compared with NCs. Further-
more, both overeating and nonovereating patients with
bvFTD had lower baseline cortisol levels, higher peak
insulin, and lower peak glucose levels compared with
NCs although the differences for overeating patients
with bvFTD were only at trend levels. This pattern of
hormonal changes is consistent with a satiated state and
should decrease food intake. In contrast, levels of the
anorectic hormone leptin were higher in overeating pa-
tients with bvFTD compared with NCs at both baseline
Figure 3 Pre- and postprandial hormone levels
Fasting and postprandial (breakfast eaten between 0 and 30minutes) ghrelin, cortisol, insulin, and glucose levels in patients
with bvFTD compared with patients with AD and healthy controls (graphs A, C, E, and G). Fasting and postprandial ghrelin,
cortisol, insulin, and glucose levels in bvFTD overeaters compared with bvFTD nonovereaters, non-bvFTD overeaters, non-
bvFTD nonovereaters, and healthy controls (graphs B, D, F, and H) (*p, 0.05;1p, 0.10). AD5 Alzheimer disease; bvFTD5
behavioral variant frontotemporal dementia; NC 5 normal control.
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time points, while leptin levels were not different
between nonovereating patients with bvFTD and NCs
(figure 4B). Non-bvFTD nonovereaters had ghrelin val-
ues similar to NCs across the entire session but lower
glucose values at130 minutes and1120 minutes. PYY
levels in both overeating and nonovereating patients
were similar to levels in NCs (figure 4D).
DISCUSSION In the present study, patients with
bvFTD had lower levels of ghrelin and cortisol and
higher peak levels of insulin compared with NCs.
Ghrelin and cortisol are well-documented prophagic
hormones, while insulin is a satiety-promoting
hormone that regulates glucose levels.3,12 Therefore,
the hormonal pattern found in patients with bvFTD
is consistent with a satiated state, which should decrease
food intake, but nonetheless, patients with bvFTD
commonly overeat. Our data, therefore, do not support
the hypothesis that hormonal abnormalities promote
overeating in bvFTD. Instead, it appears that the
overeating that results from loss of brain-based
inhibitory signals in bvFTD cannot be overridden
by appropriate compensatory hormonal responses.
Additionally, only patients with bvFTD who overate
in the laboratory and therefore likely had particularly
severe eating abnormalities had elevated levels of leptin,
a hormone that functions to decrease feeding behavior
and maintain energy homeostasis.13 Therefore, elevations
in this hormone may be specifically related to severe
overeating.
Ghrelin is a potent prophagic hormone synthesized
in the gastric oxyntic mucosa3 that increases before meal
initiation, decreases during meal consumption in asso-
ciation with decreasing hunger, and increases with food
restriction in healthy individuals.7 In response to weight
loss such as in anorexia; cancer cachexia; liver, heart, or
kidney failure–related cachexia; and diet-induced
weight loss, ghrelin levels increase,14–19 while in response
to weight gain in obesity and forced feeding, ghrelin
levels decrease and remain low during and between
meals.20 Additionally, when weight normalizes in these
disorders, ghrelin levels and dynamics also normalize.16
In our bvFTD patient group, ghrelin levels were low
despite normal weight and frequent overeating. This
pattern is similar to that seen in binge eating disorder
(BED), a psychiatric disorder characterized by episodic
Figure 4 Preprandial leptin and PYY
Fasting leptin and PYY levels in patients with bvFTD compared with patients with AD and healthy controls (graphs A and C).
Fasting leptin and PYY levels in bvFTD overeaters compared with bvFTD nonovereaters, non-bvFTD overeaters, non-bvFTD
nonovereaters, and healthy controls (graphs B and D) (*p , 0.05; 1p, 0.10). AD 5 Alzheimer disease; bvFTD 5 behavioral
variant frontotemporal dementia; NC 5 normal control; PYY 5 peptide YY.
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out-of-control binge eating.21 Patients with BED have
low levels of ghrelin before and during meals20–22 even
compared with BMI-matched, non–binge eating con-
trols.20 Patients with BED also have lower levels of
cortisol23 and higher peak postprandial levels of the
anorectic hormone insulin,20 similar to the pattern in
bvFTD. It has been hypothesized that these hormonal
abnormalities represent a compensatory response to
compulsive overeating in BED,20,21 which may also
be the case in bvFTD. However, both overeating
and nonovereating patients with bvFTD showed iden-
tical changes in levels of ghrelin, cortisol, and insulin,
which suggests that eating abnormalities may not be
the sole drivers of these hormonal changes in bvFTD.
However, our laboratory feeding paradigm likely
underestimated real-world rates of overeating because
more than 80% of patients with bvFTD develop feed-
ing abnormalities during the course of their illness,2
and we found no differences in NPI eating subscores
between overeating and nonovereating patients with
bvFTD. Thus, the “overeating” patients with bvFTD
in our study likely represent patients with particularly
severe overeating abnormalities.
Only patients with bvFTD who overate in the lab-
oratory had higher levels of leptin compared with NCs.
Leptin is secreted from adipose tissue, decreases feeding
behavior, and is a long-term marker for nutritional sta-
tus.3 The only other study to quantify leptin levels in
patients with bvFTD found that only female patients
with an FTD-spectrum phenotype had elevated levels
of leptin compared with sex-matched patients with AD
dementia,24 and this effect was particularly pronounced
for the FTD-spectrum females who also had eating
disturbances. Although we did not find sex differences
in our study, this may be attributable to the small num-
ber of women in our sample. Additionally, most studies
report higher levels of leptin in patients with BED even
controlling for BMI.25 Taken together with this previ-
ous research, our findings indicate that elevated leptin
levels may be specifically associated with severe overeat-
ing in bvFTD.
Eating abnormalities are likely an instance of a more
general pattern of behavioral disinhibition in bvFTD,
which manifests as inappropriate social behavior, envi-
ronmental dependency, and substance abuse.1,26 Previous
work indicates that overeating patients with bvFTD have
damage to a right-sided orbitofrontal-insular-striatal cir-
cuit1 and that patients with bvFTD develop pathologi-
cally enlarged ventral tegmental areas (VTAs) (a key
dopaminergic center) compared with healthy controls,
which is associated with greater severity of disinhibited
eating and worse overall behavioral impairment.8 Previ-
ous work also indicates that patients with bvFTD have
impaired top-down cognitive control circuitry that con-
tributes to their behavioral disinhibition. Accumulating
evidence demonstrates that peripheral hormones such as
ghrelin, insulin, and cortisol normally function to regu-
late these same dopaminergic and top-down circuits.3–7
For example, ghrelin administration stimulates food
reward–related brain areas including the VTA, striatum,
amygdala, insula, and medial orbitofrontal cortex that are
implicated in the hedonic aspects of feeding, and these
activations correlate with ghrelin-induced subjective feel-
ings of hunger.5 Similarly, higher cortisol levels have been
associated with riskier decision making in a gambling
paradigm,27 potentiate the desire to smoke,28 and inhibit
the anterior cingulate cortex (ACC) and medial prefron-
tal cortex (PFC), important top-down cognitive control
circuits.6,29 In contrast, intranasal administration of insu-
lin inhibits the reward-related medial orbitofrontal cortex
and stimulates the ACC and dorsolateral (dl)PFC, brain
regions implicated in top-down cognitive control of eat-
ing.30 These neural regulatory effects of ghrelin, cortisol,
and insulin are also supported by extensive nonhuman
research.3,31–33 Thus, the hormonal shifts in bvFTD may
occur to compensate for the reward circuit dysfunction
(e.g., increased VTA size), decreased top-down cognitive
control (e.g., prominent ACC and dlPFC atrophy in
bvFTD), or associated disinhibited behaviors caused by
bvFTD (figure 1). Whether or not these compensatory
hormonal changes are in response to the more global
disinhibition found in bvFTD, or specifically to feeding
disinhibition similar to patients with BED, remains to be
determined.
There are several limitations to this study. The study
design, our relatively small sample sizes, and the interre-
latedness of the hormones measured do not allow con-
clusive determination of causality or brain-behavior
relationships.34–36 Also, extrapolations of these results
to neuropathologic correlations are limited, because
our patients met consensus clinical criteria for their
diagnostic syndromes, but no further information was
available about their underlying neuropathology. Pa-
tients who legitimately meet FTD consensus criteria
for the bvFTD syndromemay have one of many under-
lying neuropathologies, including a variety of tauopa-
thies, different variants of TDP-43 (transactive response
DNA binding protein 43), FUS (fused in sarcoma), and
AD.10 Additionally, while patients’ eating behaviors
were monitored in our controlled laboratory paradigm,
patients’ feeding habits may differ in their home envi-
ronments. We used patients’ caregivers as controls
because they were demographically matched to our
patients, but they may have hormonal abnormalities
related to the chronic stress of caregiving. Moreover,
our bvFTD group was predominantly male (16:3),
while our control group was largely female. Both ghre-
lin and cortisol secretion are sexually dimorphic with
higher levels in females.37,38 However, we controlled for
sex in our analyses. Additionally, many of our patients
were taking medications that affect hunger and weight
(table), and these effects could not be adequately
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controlled for. Finally, contrary to previous studies,39
we found no differences in levels of ghrelin, cortisol,
insulin, or leptin in patients with AD dementia com-
pared with NCs. This may be because our patients with
AD dementia were younger as they were age-matched
to the patients with bvFTD.
In conclusion, we identified that patients with
bvFTD, relative to healthy age-matched controls, have
abnormally low levels of ghrelin and cortisol, and high
levels of insulin, regardless of overeating behaviors, as
measured through a laboratory-based feeding paradigm.
In addition, only patients with bvFTDwho overate had
elevated leptin. These findings suggest that patients
with bvFTD overeat despite their hormonal milieu.
Further research is needed to explore the underlying
mechanisms of this hormonal dysfunction.
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